Jennifer L. Good
Known title: DirectorCIK: 0001229245
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
TRVI releases Q2 2026 earnings and makes Raymond James top health list. Trevi Therapeutics held its Q2 2026 earnings call, sharing the latest financial and operational results. In a separate note, Raymond James analysts listed the stock among their top four healthcare picks. The earnings discussion and analyst endorsement may draw additional attention to the company. The shares are trading close to the upper end of their 52‑week range.
Transaction History
| RYTM | ▲ Buy | Option Exercise | 4,712 | — | 6/23/2026 | View on chart |
| RYTM | ▲ Buy | Option Exercise | 4,000 | — | 6/18/2025 | View on chart |
| TRVI | ▲ Buy | Option Exercise | 5,263 | $8K | 3/21/2025 | View on chart |
| TRVI | ▼ Sell | Open Market | 5,263 | $35K | 3/21/2025 | View on chart |
| RYTM | ▲ Buy | Option Exercise | 15,000 | $344K | 9/17/2024 | View on chart |
| RYTM | ▲ Buy | Option Exercise | 9,250 | $198K | 9/17/2024 | View on chart |
| RYTM | ▲ Buy | Option Exercise | 7,501 | $142K | 9/17/2024 | View on chart |
| RYTM | ▼ Sell | Open Market | 31,751 | $1.7M | 9/17/2024 | View on chart |
| RYTM | ▲ Buy | Option Exercise | 12,900 | $296K | 9/9/2024 | View on chart |
| RYTM | ▲ Buy | Option Exercise | 4,305 | $92K | 9/9/2024 | View on chart |
| TRVI | ▲ Buy | Option Exercise | 1,840 | $3K | 9/9/2024 | View on chart |
| RYTM | ▲ Buy | Option Exercise | 1,736 | $33K | 9/9/2024 | View on chart |
| RYTM | ▲ Buy | Option Exercise | 18,300 | $76K | 9/9/2024 | View on chart |
| RYTM | ▼ Sell | Open Market | 37,241 | $1.9M | 9/9/2024 | View on chart |
| TRVI | ▼ Sell | Open Market | 1,840 | $6K | 9/9/2024 | View on chart |
| TRVI | ▲ Buy | Option Exercise | 4,219 | $6K | 9/6/2024 | View on chart |
| TRVI | ▼ Sell | Open Market | 4,219 | $13K | 9/6/2024 | View on chart |
| TRVI | ▲ Buy | Option Exercise | 40,277 | $58K | 9/5/2024 | View on chart |
| TRVI | ▼ Sell | Open Market | 40,277 | $125K | 9/5/2024 | View on chart |
| TRVI | ▲ Buy | Option Exercise | 10,981 | $16K | 9/4/2024 | View on chart |
| TRVI | ▼ Sell | Open Market | 10,981 | $33K | 9/4/2024 | View on chart |
| TRVI | ▲ Buy | Option Exercise | 3,863 | $6K | 9/3/2024 | View on chart |
| TRVI | ▼ Sell | Open Market | 3,863 | $12K | 9/3/2024 | View on chart |
| RYTM | ▲ Buy | Option Exercise | 2,100 | $48K | 8/26/2024 | View on chart |
| RYTM | ▲ Buy | Option Exercise | 4,945 | $106K | 8/26/2024 | View on chart |
| RYTM | ▲ Buy | Option Exercise | 5,763 | $109K | 8/26/2024 | View on chart |
| RYTM | ▼ Sell | Open Market | 14,508 | $726K | 8/26/2024 | View on chart |
| RYTM | ▲ Buy | Option Exercise | 1,700 | $7K | 8/26/2024 | View on chart |
| RYTM | ▲ Buy | Option Exercise | 3,000 | — | 6/21/2024 | View on chart |
| TRVI | ▲ Buy | Option Exercise | 25,037 | $55K | 5/20/2024 | View on chart |
| TRVI | ▼ Sell | Open Market | 25,037 | $72K | 5/20/2024 | View on chart |
| TRVI | ▲ Buy | Option Exercise | 4,578 | $10K | 5/10/2024 | View on chart |
| TRVI | ▼ Sell | Open Market | 4,578 | $13K | 5/10/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
RYTM: RBC raises price target to $159, maintains Outperform
RBC Capital kept its Outperform rating on Rhythm Pharmaceuticals and lifted its price target to $159. The new target sits well above the stock’s 52‑week high of $122.20 and higher than the consensus analyst target of $138.59. A recent Benzinga piece also highlighted the stock’s five‑year total return, underscoring its past performance. These developments may influence market perception of the company’s growth prospects.
RYTM: RBC raises price target to $159, maintains Outperform. RBC Capital kept its Outperform rating on Rhythm Pharmaceuticals and lifted its price target to $159. The new target sits well above the stock’s 52‑week high of $122.20 and higher than the consensus analyst target of $138.59. A recent Benzinga piece also highlighted the stock’s five‑year total return, underscoring its past performance. These developments may influence market perception of the company’s growth prospects.